Clinical Edge Journal Scan

Bone Erosions Highly Prevalent in Early, Untreated PsA


 

Key clinical point: A quarter of patients with early psoriatic arthritis who were naive to disease-modifying antirheumatic drugs (DMARD) reported bone erosions, with a decreased prevalence being observed in patients with shorter duration of PsA symptoms (<8 months).

Major finding: Overall, 4655 hand and feet joints were assessed in 122 patients, of whom 24.6% patients had bone erosions at baseline, with higher Disease Activity features observed in patients who did vs did not have bone erosions (P < .05). Prevalence of erosion was less in patients who had a <8 months vs >24 months of PsA symptoms (17.5% vs 24.3%).

Study details: This study included 122 newly diagnosed, DMARD-naive patients with early PsA from the Leeds Spondyloarthropathy Register for Research and Observation cohort who were assessed for bone erosions using conventional radiography or ultrasound.

Disclosures: This study was supported by the UK National Institute for Health Research Leeds Biomedical Research Centre. Sayam R. Dubash received support from Leeds Cares charity. The other authors declared no conflicts of interest.

Source: Hen O, Di Matteo A, Dubash SR, et al. High prevalence of radiographic erosions in early, untreated PsA: Results from the SpARRO cohort. RMD Open. 2024;10:e003841 (Apr 5). doi: 10.1136/rmdopen-2023-003841 Source

Recommended Reading

Tuberculosis Screening Gaps Persist in New DMARD Users
MDedge Rheumatology
Congress Directly Provides $10 Million for Arthritis Research for First Time
MDedge Rheumatology
A 30-Year-Old White Female Presented With a 4-Month History of Scaly, Erythematous Patches and Plaques on Her Trunk and Extremities
MDedge Rheumatology
Worldwide Prevalence of Psoriatic Arthritis More Precisely Determined
MDedge Rheumatology
Favorable Efficacy Outcomes with Bimekizumab vs Guselkumab in PsA
MDedge Rheumatology
Low Risk for Serious Infections Among New Users of Targeted Therapies in PsA
MDedge Rheumatology
Risankizumab Offers Long-term Protection Against PsA
MDedge Rheumatology
Durable Improvements Across PsA Disease Domains with Guselkumab
MDedge Rheumatology
Enthesitis or Dactylitis Remission Associated with Improved Patient-Reported Outcomes in PsA
MDedge Rheumatology
Deucravacitinib Improves Patient-Reported Outcomes in PsA
MDedge Rheumatology